Moleculent Secures $20M to Map the Secret Conversations Between Cells

STOCKHOLM – April 30, 2026 – Moleculent AB, a Swedish life sciences firm developing technology to visualize how cells communicate, has closed a $20 million financing round to accelerate its expansion into the United States and scale its pioneering platform. The funding round was led by Nordic private equity firm Rubicon Healthcare Partners, with strong participation from existing investors including the highly regarded ARCH Venture Partners and Eir Ventures.

The capital injection is earmarked to expand the company's Techstart Early Access Program, build out its commercial operations in the U.S., and drive the full commercial launch of its automated instrument designed to map cellular interactions at an unprecedented scale.

“The market is telling us it’s ready,” said Olle Ericsson, PhD, Co-Founder and CEO of Moleculent. “We are seeing surging demand from leading research institutions and pharmaceutical partners across both Europe and the US. This new funding allows us to move more aggressively as we work to put this platform into the hands of the scientists decoding the cellular conversations that drive human disease.”

Decoding the Science of Cellular Dialogue

For decades, researchers have been able to identify different cell types within tissue and catalog the proteins they express. However, a fundamental gap has remained: understanding how these cells directly interact and communicate with each other in their natural environment. Moleculent aims to fill this void with a technology it calls “functional profiling.”

At the heart of its platform is a proprietary method known as the Proximity Ligation Assay (PLA). This technique acts like a molecular detective, identifying when proteins on the surfaces of adjacent cells are close enough to be considered 'in conversation.' It converts this proximity into a detectable DNA signal, creating a high-resolution map of the cellular social network within a tissue sample. Crucially, the platform also types the cells involved, providing essential context to these interactions. This allows researchers to move beyond inference and directly observe the intricate dialogues that orchestrate health and drive disease.

Nigel Jamieson, a Professor of Pancreatic and Liver Surgery at the University of Glasgow and an inaugural partner in Moleculent's early access program, highlighted the technology's transformative potential. “For years, we’ve been able to see where cells are and what they express, but we couldn’t see how they actually talk to each other in the tissue,” he said. “Moleculent changes that completely—this is the kind of tool that reshapes entire research programs.”

A Defining Moment in a Booming Market

The financing arrives as the spatial biology market—the sector focused on analyzing cells in their 3D context—is experiencing explosive growth. Valued at an estimated $1.48 billion in 2026, the market is projected to expand at a compound annual growth rate of over 19%, driven by its immense potential to advance cancer research, immunology, and neuroscience. While established players like 10x Genomics and Akoya Biosciences have pioneered spatial gene expression, Moleculent is carving out a unique and valuable niche.

By focusing on the functional interactions between cells rather than just their genetic or protein content, the company is offering a new layer of biological insight. The firm is developing an automated instrument to make this complex analysis accessible, reproducible, and scalable for translational research labs globally, a key step in moving the technology from a niche tool to a laboratory staple.

This distinct approach caught the eye of its new lead investor. “We have evaluated platforms across the life sciences tools landscape for years, and Moleculent stands out as truly category-defining,” stated Ole Dahlberg, Managing Partner at Rubicon Healthcare Partners. “The company’s approach to directly mapping cell-cell communication has the potential to transform how researchers study disease and develop therapies.”

Fortifying the Board with Strategic Expertise

The investment is more than just a financial endorsement; it brings significant strategic expertise to the Swedish firm. As part of the financing, Ole Dahlberg joins Moleculent's Board of Directors. His extensive 20-year career in the life sciences includes senior leadership roles at industry giants Thermo Fisher Scientific, where he led Cell Biology and Sample Preparation, as well as Qiagen and Life Technologies. His deep operational experience in scaling life science tool companies is expected to be invaluable as Moleculent navigates its U.S. expansion and commercial launch.

The continued participation of ARCH Venture Partners, a premier venture capital firm known for building transformative life science companies from the ground up, further solidifies the strength of the investor syndicate. ARCH, which co-led Moleculent's Series A round in 2024, has a track record of backing foundational companies like Illumina, signaling its long-term conviction in Moleculent's platform.

“With Rubicon joining ARCH and Eir Ventures, we now have a syndicate of builders with successful track records of scaling life science companies from breakthrough technology to global impact,” Ericsson noted, emphasizing the strategic value of the partnership.

From Early Access to Global Impact

The immediate focus for the new capital will be accelerating Moleculent’s go-to-market strategy. A significant portion will be used to expand the Techstart Early Access Program, which provides select academic and biopharma partners with priority access to the platform. This program has already generated crucial validation and demonstrated strong demand from world-class institutions.

Simultaneously, the company will establish a robust commercial footprint in the United States, the world's largest market for life science tools and pharmaceutical research. This push will be supported by the development and eventual launch of the fully automated instrument, which promises to minimize hands-on time and maximize reproducibility for large-scale studies. By tackling the complexity and scalability challenges that often hinder the adoption of advanced technologies, Moleculent is positioning its platform not just as a scientific breakthrough, but as a practical tool poised to unlock the next generation of insights into human health and disease.